Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To describe the incidence of acute respiratory infections (ARI) during the first year in infants born before 32 weeks' gestation, and to analyze and study the risk factors as well as factors associated with oxygen requirement among infants with an ARI, in the palivizumab era

Next Previous
Trial Profile

To describe the incidence of acute respiratory infections (ARI) during the first year in infants born before 32 weeks' gestation, and to analyze and study the risk factors as well as factors associated with oxygen requirement among infants with an ARI, in the palivizumab era

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Acronyms Epipage-2

Most Recent Events

  • 26 Dec 2021 Results (n=492) of an analysis comparing the different antibiotic prophylaxis administered after preterm premature rupture of membranes to determine if any were associated with differences in obstetric and/or neonatal outcomes and/or neurodevelopmental outcomes at two years of corrected age published in the BJOG: An International Journal of Obstetrics and Gynaecology
  • 09 Jul 2021 New trial record
  • 01 Jun 2021 Results published in the European Journal of Pediatrics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top